CRON is one of the easiest longs in the market rn with growing margins and a fortress balance sheet with a massive cash position almost equal to book value. TLDR: 💨Earnings inflection: Q2 revenue rose 58% YoY to $53M, while adjusted EBITDA reached $13.1M versus $1.7M a year earlier. 💨Margins are expanding: Gross profit nearly doubled to $28.5M as higher-margin Israel/Germany sales, which carry no excise taxes, became a larger mix of revenue. 💨Real consumer-brand momentum: Spinach is Canada’s #2 overall cannabis brand and #1 in both edibles and vapes—evidence that growth is not solely commodity flower. 💨Europe just became a tangible growth leg: The completed CanAdelaar acquisition gives CRON the leading position in the Netherlands’ adult-use pilot market, bought at only ~1.4× annualized revenue. 💨Balance-sheet support and buybacks: CRON had roughly $827M of cash/investments/deposits against $62M of total liabilities at Q2, and retired 12.25M shares in the first half—reducing dilution and supporting per-share upside.